CRONOS GROUP INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.34 USD | +0.86% |
|
+0.43% | +11.96% |
| 27/06 | Cronos Group Inc. Brand Spinach®? Celebrates Summer with New Launches | CI |
| 21/06 | Cronos Group Inc. Elects Murray Garnick as Director | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 55% by 2026.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The stock, which is currently worth 2024 to 0.26 times its sales, is clearly overvalued in comparison with peers.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +11.96% | 907M | - | ||
| +28.10% | 5.6B | B- | ||
| -33.42% | 3.53B | C+ | ||
| -3.33% | 3.03B | C | ||
| -26.20% | 2.58B | B- | ||
| -9.99% | 2.31B | - | D+ | |
| +40.09% | 1.86B | - | ||
| +40.90% | 1.45B | - | ||
| -12.94% | 1.43B | - | - | |
| +46.67% | 1.41B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CRON Stock
- CRON Stock
- Ratings Cronos Group Inc.
